Clinical Trial

Impact of GDMT in Uncontrolled Asthma Patients Receiving MHD Inhaled Corticosteroids + Long-acting β2 Agonist

Study acronym: PRECISION
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate whether GDMT can bring significant benefits to disease management in uncontrolled asthma patients receiving medium- to high-dose ICS-LABA. * The intervention period will be up to 48 weeks; * The frequency of follow-up is every 12 weeks.
Trial Details
NCT Number NCT07718724
Lead Sponsor AstraZeneca
Conditions Uncontrolled Asthma
Enrollment 540 participants
Start Date 2026-08-15
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-22